Keywords: astrazeneca, completes, cerovive, ph, ii, enrollment, early
AstraZeneca completes Cerovive Ph II enrollment early
Article | 13 December 2004
Anglo-Swedish drug major AstraZeneca, exclusive licensee of US firm Renovis' Cerovive (NXY-059), has, ahead of schedule, completed the enrollment of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
